Volume 45, Issue 4, Pages (October 2006)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Host – hepatitis C viral interactions: The role of genetics
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Hepatic CD141+IFNλ+ DC subset: One against all?
Unraveling the Role of PD-1/PD-L Interactions in Persistent Hepatotropic Infections: Potential for Therapeutic Application?  Henry Radziewicz, Holly L.
Pathological roles of purinergic signaling in the liver
Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR  Nicolas Marsollier, Pascal Ferré,
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 52, Issue 3, Pages (March 2010)
Immigration and viral hepatitis
Volume 66, Issue 1, Pages 1-4 (January 2017)
The evidence supports a viral aetiology for primary biliary cirrhosis
Living donor liver transplantation: is the hype over?
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Mesenchymal stromal cell therapy for liver diseases
Biology of the immunomodulatory molecule HLA-G in human liver diseases
The progenitor cell dilemma: Cellular and functional heterogeneity in assistance or escalation of liver injury  Veronika Lukacs-Kornek, Frank Lammert 
Volume 69, Issue 4, Pages (October 2018)
From immunosuppression to tolerance
Hepatitis C core protein – The “core” of immune deception?
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Burcin Ekser, Eric Lagasse  Journal of Hepatology 
Targeting gut flora to prevent progression of hepatocellular carcinoma
Targets for immunotherapy of liver cancer
Volume 53, Issue 4, Pages (October 2010)
Inhibition of mammalian target of rapamycin: Two goals with one shot?
Volume 62, Issue 3, Pages (March 2015)
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Autophagy in the liver Journal of Hepatology
Volume 59, Issue 3, Pages (September 2013)
EASL Clinical Practice Guidelines: Wilson’s disease
Dendritic cells: regulators of hepatic immunity or tolerance?
Mona Malz, Federico Pinna, Peter Schirmacher, Kai Breuhahn 
Targeting STAT3 in hepatocellular carcinoma: Sorafenib again…
TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit  Kristen E. Pauken,
Cannabinoid signaling and liver therapeutics
Volume 50, Issue 4, Pages (April 2009)
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Non-invasive diagnosis and biomarkers in alcohol-related liver disease
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Volume 143, Issue 1, Pages (July 2012)
Fei Xiao, Jane A. McKeating, Thomas F. Baumert  Journal of Hepatology 
Salvatore Papa, Concetta Bubici  Journal of Hepatology 
Immigration and viral hepatitis
The potential of induced pluripotent stem cell derived hepatocytes
HIV and HLA Class I: An Evolving Relationship
Volume 63, Issue 1, Pages (July 2015)
Silvia Affò, Ramón Bataller  Journal of Hepatology 
HCV animal models and liver disease
Statins: Old drugs as new therapy for liver diseases?
Ana Lleo, M. Eric Gershwin, Alberto Mantovani, Pietro Invernizzi 
Janna Krueger, Christopher E. Rudd  Immunity 
Volume 60, Issue 6, Pages (June 2014)
Reply to: “Flow cytometry makes all the difference”
Pathogenesis of cholestatic hepatitis C
EpCAM in hepatocytes and their progenitors
Therapy of Alopecia Areata: On the Cusp and in the Future
Genetics of hepatocellular carcinoma: The next generation
Host – hepatitis C viral interactions: The role of genetics
Niya Aleksieva, Stuart J. Forbes  Journal of Hepatology 
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Volume 60, Issue 6, Pages (June 2014)
Presentation transcript:

Volume 45, Issue 4, Pages 468-472 (October 2006) Turning on the off switch: Regulation of anti-viral T cell responses in the liver by the PD- 1/PD-L1 pathway  Arash Grakoui, E. John Wherry, Holly L. Hanson, Christopher Walker, Rafi Ahmed  Journal of Hepatology  Volume 45, Issue 4, Pages 468-472 (October 2006) DOI: 10.1016/j.jhep.2006.07.009 Copyright © 2006 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Achieving T cell balance. Pathogen-specific CD8+ T cells are “turned on” through interaction of their TCR with MHC I presenting antigen in the presence of appropriate costimulation. These same T cells may be “turned off” through the interaction of PD-1 on their cell surface and PD-L1 expressed on hepatocytes and liver-resident parenchymal cells. Journal of Hepatology 2006 45, 468-472DOI: (10.1016/j.jhep.2006.07.009) Copyright © 2006 European Association for the Study of the Liver Terms and Conditions

Fig. 2 T cell activation and proliferation require positive signaling through the TCR receptor complex. The interaction of PD-1 with PD-L1 leads to phosphorylation of the ITSM domain of PD-1, recruitment of SHP-2, and cell cycle arrest. Journal of Hepatology 2006 45, 468-472DOI: (10.1016/j.jhep.2006.07.009) Copyright © 2006 European Association for the Study of the Liver Terms and Conditions